Clinical trial
The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study
NCT00870493 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study
- Lead sponsor
- Chinese University of Hong Kong
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- July 31, 2012
- Enrollment
- 22 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
iga nephropathy